Clinical studies of an IL-6R inhibitor that inhibits the binding of IL-6 to its receptor, tocilizumab, have shown in patients with cancer cachexia the reduction of plasma IL-6 levels, the alleviation of muscle mass loss without affecting tumor proliferation [8, 71, 72]. The gene discussed is IL6; the disease is neoplasm.